摘要
目的基于网络药理学方法研究半夏泻心汤(Banxia Xiexin Tang,BXT)抗消化性溃疡(Peptic Ulcer,PU)的作用机制。方法通过中药系统药理学数据库(TCMSP)获得BXT主要活性成分,采用Swiss Target Prediction平台预测活性成分的潜在靶点,并检索Therapeutic Target Database等疾病靶点数据库,以获得BXT抗PU的作用靶点。借助String数据库和Cytoscape 3.2.1软件构建蛋白质相互作用网络(PPI),筛选degree值排名前10的靶点。通过Systems Dock Web Site软件将BXT中活性成分与重要的靶蛋白进行分子对接。采用Metascape平台对BXT抗PU作用靶点进行KEGG通路分析。结果从BXT中筛选出156个活性成分,49个与BXT抗PU相关的作用靶点;经KEGG通路富集分析,发现其可调节内分泌耐药、PI3K-Akt、表皮生长因子受体酪氨酸激酶抑制剂耐药等信号通路。结论半夏泻心汤抗PU多与抗炎、抗幽门螺旋杆菌、增加胃肠道血流量与胃肠黏膜碳酸氢盐分泌量相关。
Objective To study the mechanism of Banxia Xiexin Tang(BXT)for Anti-Peptic Ulcer(PU)based on network pharmacology.Methods The active ingredients of BXT was obtained from the TCMSP database.Potential targets of the active ingredients were predicted by Swiss Target Prediction and compared with the five disease target databases included Online Mendelian Inheritance in Man(OMIM),Therapeutic Target Database(TTD),Disease Gene Search Engine(DiGSeE),Drug Bank,and Human Phenotype Ontology(HPO),to obtain the targets of BXT for anti-PU.The target protein interaction(PPI)network was constructed based on the String database and Cytoscape3.2.1 software,and the top 10 target proteins were selected by degree.Molecular docking between the active components of BXT and the major targets was carried out using Systems Dock Web Site.The target enrichment analysis of KEGG pathways were analyzed by Metascape database.Results A total of 156 active components and 49 anti-PU-related targets were screened from BXT.After enrichment analysis by KEGG pathway,it was found to regulate endocrine resistance,PI3 K-Akt signaling pathway,Epidermal growth factor receptor tyrosine kinase inhibitor resistance and other signaling pathways.Conclusion The result of this study preliminarily reveals the effective mechanism of BXT in treating PU,which is related to anti-inflammatory,anti-Helicobacter pylori,increase of gastrointestinal blood flow and secretion of bicarbonate.
作者
彭陈文
刘凤斌
王森
何沛聪
孙茗威
甄伟龙
张家振
文彦钧
PENG Chenwen;LIU Fengbin;WANG Sen;HE Peicong;SUN Mingwei;ZHEN Weilong;ZHANG Jiazhen;WEN Yanjun(First Clinical Medical College,Guangzhou University of Chinese Medicine Guangzhou 510405 Guangdong,China;The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405 Guangdong,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2019年第12期1479-1484,共6页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
国家自然科学基金项目（81774264）
广东省中医药局建设中医药强省专项资金[粤中医函（2015)19号]
广州中医药大学一流学科科研研究重点项目[广中医规划（2018)6号]
大学生创新创业训练计划国家级项目（201910572022）
作者简介
彭陈文,男,本科,研究方向:脾胃病临床与基础研究,Email:1052740027@qq.com;通信作者:刘凤斌,男,教授,博士研究生导师,研究方向:脾胃病临床与基础研究,Email:liufb163@163.com。
